M/R

(redirected from Minocycline and Rifampin)
AcronymDefinition
M/RMap/Reduce (programming model)
M/RMixture Ratio
M/RMental Retardation
M/RMain Rotor (helicopter)
M/RMoisture Resistant (gypsum wallboard type)
M/RMargin requirement
M/RMinocycline and Rifampin (antimicrobial agents)
References in periodicals archive ?
Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
The components of the prosthesis (pump and cuff) can be or not impregnated InhibiZone antibiotic (minocycline and rifampin).
The Envelope elutes antimicrobial agents Minocycline and Rifampin locally into the tissue for a minimum of seven days.
Bloomington, Ind.-based Cook Medical's Spectrum catheters include the antibiotics minocycline and rifampin and meet the newly released 1A recommendation from the Centers for Disease Control and Prevention (CDC) for reducing catheter-related bloodstream infections (CRBSIs) if maximal sterile barrier precautions haven't helped a facility reach its [infection prevention] goal.
PATIENT _________________________________________________ SPECIMEN TYPE ___________________________________________ DATE COLLECTED __________________________________________ PHYSICIAN _______________________________________________ Addendum to Methicillin-resistant Staphylococcal Sensitivity Testing Report This organism is sensitive to both minocycline and rifampin. Oral combination therapy with these two antibiotics may be a useful alternative to vancomycin.
Catheters impregnated with minocycline and rifampin are commercially available.
Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infection.
It is designed to stabilize the device after implantation while releasing two antimicrobial agents, minocycline and rifampin, over a minimum of seven days to help prevent surgical-site infections, which are associated with substantial morbidity, mortality and cost.
The TYRX Absorbable Antibacterial Envelope contains a combination of two antibacterial agents, minocycline and rifampin, which have been shown to reduce medical device infection in multiple randomized control trials.
(19) found that catheters impregnated with minocycline and rifampin were less likely to be colonized than those impregnated with chlorhexidine and silver sulfadiazine.
The TYRX Absorbable Antibacterial Envelope is a mesh envelope that holds an implantable cardiac device and is designed to stabilize the device after implantation while releasing antimicrobial agents, minocycline and rifampin, over a minimum of seven days.
The PICC's combination of minocycline and rifampin has proven to be an effective mixture so far in reducing the liklihood of CRBSIs while simultaneously avoiding antibiotic resistance.